Cancer Research Technology grants Waypharm option to novel platinum agents

Cancer Research Technology Limited (CRT), the cancer-focused development and commercialisation company, today announce that Waypharm S.A.S (Waypharm) has secured rights to evaluate Thioplatin a novel hypoxia-responsive platinum-based cancer therapy, from CRT.

Under the terms of the agreement, CRT has granted Waypharm an exclusive 6-month option to in-license worldwide development and commercialisation rights to the Thioplatin programme. CRT will receive an upfront payment for the option, and has agreed licensing fees, development-related milestones and royalty payments following successful development and commercialisation by Waypharm.

The Thioplatin programme stems from research conducted by Professor Eberhard Amtmann of the Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, and Dr Gerhard Schilling of the University of Heidelberg. The scientists have developed platinum compounds that display enhanced activity under the hypoxic conditions of solid tumours. Such tumour selectivity could allow the administration of higher doses of this new class of platinum drug without the usual neutropenic and neuropathological toxicities that are associated with other platinum drugs.

Within the programme a lead compound, TP-2, has been selected and will be licensed along with a package of preclinical data, including formulation and stability studies. Waypharm will use its formulation expertise and recently accredited production facilities outside of Paris, to optimise a liposomal formulation for entry into Phase I trials.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel bladder cancer treatment gains MHRA approval in the UK